PCOS and Hair Loss: How Hormones Drive the Pattern

PCOS hair loss has a particular character that often confuses patients on first encounter: hair on the scalp grows thinner while hair on the face, chest, or abdomen grows coarser and darker. The same hormone, testosterone (and its more potent metabolite, DHT), seems to be doing two opposite things at once. The apparent paradox has a clean physiological explanation, and understanding it makes the treatment approach much easier to follow. Polycystic ovary syndrome (PCOS) is one of the most common endocrine conditions in women of reproductive age, and scalp hair loss is one of the more under-recognized features.

This page walks through how PCOS produces hair loss, why scalp and body hair behave differently in response to the same hormones, what laboratory evaluation typically involves, and what evidence-based treatments are used.

The pathophysiology behind PCOS

PCOS is a syndrome rather than a single disease, and the diagnostic criteria require two of three features: irregular ovulation, clinical or biochemical evidence of androgen excess, and characteristic ovarian appearance on imaging. Clinical androgen excess can manifest as acne, excess facial or body hair (hirsutism), or scalp hair thinning.

Several interlinked drivers contribute to the picture:

• Insulin resistance. A large proportion of women with PCOS have insulin resistance, often regardless of body weight. Elevated insulin acts on the ovaries to stimulate androgen production and reduces hepatic production of sex hormone binding globulin (SHBG). With less SHBG, more testosterone circulates in its free, biologically active form.
• Ovarian and adrenal androgen production. The ovaries in PCOS produce more androgens than typical, and adrenal androgen contribution is also somewhat elevated in many women with the syndrome.
• Disrupted ovulation. Irregular or absent ovulation reduces progesterone production, which can further alter the hormonal environment.

The net result, for hair, is a higher level of androgen activity at follicles that are sensitive to it. The fundamental hair-relevant hormone is the same one that drives pattern hair loss more generally: DHT, the more potent metabolite of testosterone produced by 5-alpha reductase.

Why androgens cause both scalp thinning and body hair growth

This is the apparent paradox. Same hormone, opposite effects in different parts of the body. The explanation lies in how different follicles respond to androgens.

Hair follicles fall into roughly three categories with respect to androgen sensitivity:

• Androgen-dependent follicles. These produce hair only when androgens are present, or grow more substantially in response to androgens. Examples include facial hair (beard area), chest hair, abdominal hair, and pubic hair (after puberty). At baseline in adult women, these follicles produce only fine vellus hair. Higher androgen exposure converts vellus hair to terminal (coarse, pigmented) hair, the process that produces hirsutism.
• Androgen-sensitive follicles. These produce hair regardless of androgens but respond to them by miniaturizing. Scalp follicles in genetically susceptible women fall here. Higher androgen exposure progressively shortens the anagen phase and produces finer hairs over successive cycles, the follicle miniaturization that underlies pattern hair loss.
• Androgen-independent follicles. These do not change appreciably with androgen exposure. Eyebrows and eyelashes are largely in this group.

So when androgen activity rises in PCOS, the body-hair follicles do what androgens tell them to (grow coarser and darker), and the susceptible scalp follicles do what androgens tell them to (miniaturize). It is the same signal, interpreted differently by different cells. The receptor responses, the local enzymes (including 5-alpha reductase activity), and the surrounding tissue all contribute to that difference.

Free versus total testosterone

When physicians evaluate androgen status in suspected PCOS, the distinction between total testosterone and free testosterone matters.

Total testosterone is the sum of all testosterone in circulation, including the large fraction bound to SHBG and inactive. Free testosterone is the unbound portion that can interact with receptors and exert biological effects. In PCOS, insulin-driven SHBG suppression often pushes free testosterone up while leaving total testosterone in or near the normal range. A woman with classic PCOS features may have a normal total testosterone but a meaningfully elevated free testosterone or free androgen index.

Other relevant measurements include DHEAS (an adrenal androgen), 17-hydroxyprogesterone (to screen for non-classical congenital adrenal hyperplasia, which can mimic PCOS), and prolactin and TSH (to rule out other causes of menstrual irregularity). The exact panel depends on the clinical picture.

The pattern of PCOS-related scalp hair loss

PCOS-related scalp hair loss generally follows the female pattern hair loss pattern: diffuse thinning across the central scalp with preservation of the frontal hairline. In some women with substantial androgen elevation, more male-pattern features can appear, such as more prominent recession at the temples or thinning extending to the vertex, but this is less common than the central pattern.

A useful clue is the cluster of features. Scalp thinning together with new or worsening facial hair growth, persistent acne, irregular periods, or weight changes points more strongly toward an androgen-driven process than scalp thinning in isolation.

Treatment approach

PCOS hair loss is treated on two fronts: addressing the underlying hormonal environment when possible, and treating the hair loss directly. The combination is usually more effective than either alone.

Spironolactone

Spironolactone is the most common medication used for PCOS-related scalp hair loss. It blocks androgen receptors and partially reduces androgen production, attenuating the signal driving miniaturization. Doses used for hair loss are typically lower than those used for blood pressure or fluid management. Common considerations:

• Pregnancy is a contraindication because of risks to fetal development. Reliable contraception is required for women of reproductive age using spironolactone.
• Side effects can include menstrual irregularity, breast tenderness, and elevated potassium. Periodic laboratory monitoring is standard.
• Effects on hair are gradual. Four to six months of consistent use is the minimum to evaluate response, with the full benefit assessed at twelve months.

The hair loss treatment for women page has a fuller discussion of spironolactone in context.

Topical or low-dose oral minoxidil

Minoxidil works through a different mechanism (prolonging anagen, partially reversing miniaturization) and is often combined with an anti-androgen. Topical 5% foam once daily is well-studied in women. Low-dose oral minoxidil is sometimes used under physician supervision when topical use is not tolerated or has not produced adequate response. The topical vs oral minoxidil guide compares the forms.

The combination of an anti-androgen (which slows the cause of miniaturization) and minoxidil (which supports recovery of follicles) is a common practical approach in PCOS-related scalp hair loss.

Combined oral contraceptives

Some combined oral contraceptives are used in PCOS, partly for menstrual regulation and partly for the androgen-suppressing effects of the estrogen component (which raises SHBG and lowers free testosterone). Different progestins have different androgenic profiles, and selection matters. This is a decision made in collaboration with a gynecologist or primary care physician, weighing contraceptive needs, cardiovascular risk, and hair-related goals.

Insulin sensitization and weight management

When insulin resistance is a meaningful driver, addressing it can improve the overall hormonal picture. This may include lifestyle measures (regular activity, attention to dietary patterns) and, in some women, metformin under physician supervision. Weight management, when relevant, can lower insulin and reduce ovarian androgen production. These measures are not specifically hair treatments, but they address the upstream environment that is driving hair loss.

The diet and hair loss guide covers what the evidence does and does not show about diet and hair generally.

When endocrinology referral is appropriate

Many women with PCOS are managed by primary care physicians or gynecologists, sometimes in partnership with a dermatologist for hair-specific concerns. Endocrinology referral may be appropriate in certain situations:

• Severely elevated androgen levels (for example, total testosterone meaningfully above the upper limit of the female reference range), which may suggest a different cause than typical PCOS.
• Rapid onset of androgenic features (rapid hirsutism, voice deepening, clitoromegaly), which can suggest an androgen-secreting tumor and warrants prompt evaluation.
• Metabolic complications of PCOS (significant insulin resistance, type 2 diabetes, dyslipidemia) that require coordinated management.
• Suspected non-classical congenital adrenal hyperplasia based on 17-hydroxyprogesterone testing.
• Atypical features that do not fit straightforward PCOS.

For uncomplicated PCOS with scalp hair loss, primary medical management plus targeted hair treatment usually suffices.

Realistic timeline

Hair responses to medication are slow, regardless of the medication. Several specific points apply in PCOS:

• Slowing the androgen signal does not immediately reverse miniaturization. Follicles need time to recover.
• The first three to four months may show stabilization rather than improvement.
• Visible density change typically takes six to twelve months.
• Reductions in body hair from anti-androgens occur over a similar time frame and may require ongoing cosmetic measures in the interim.

Stopping treatment leads to return of androgen activity at the follicle and gradual return to the pre-treatment trajectory. PCOS is a long-term condition, and so is its hair component.

Considering medical assessment

PCOS-related hair loss responds to treatment in many women, but the right plan depends on confirming the diagnosis, identifying which drivers are most active, and selecting a medication strategy that fits the rest of the medical picture. A consultation can establish whether the pattern fits, order the right laboratory tests, and create a plan rather than guessing. How Curekey works describes the consultation process. The broader hair loss in women overview covers context, and the DHT and pattern hair loss page goes deeper on the underlying hormone biology.

PCOS hair loss is treatable, but it benefits from being understood as part of a syndrome rather than treated as an isolated cosmetic problem.